BridgeMD
Compares treatment options for Lumbar Disc Herniation
Official title High-Intensity Laser Therapy Versus Transforaminal Epidural Steroid Injection in Chronic Lumbar Disc Herniation-Related Low Back and Radicular Pain
ClinicalTrials.gov ID: NCT07688915
What this study is testing
- What it's testing
- This prospective, randomized, single-blinded, controlled clinical trial aims to compare the effectiveness of high-intensity laser therapy and fluoroscopy-guided transforaminal epidural steroid injection in patients with chronic low back pain and lumbar radiculopathy. Eligible patients will be randomized into two parallel groups.
- Time commitment: about 3 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Age between 18 and 65 years
- Diagnosis of lumbar disc herniation confirmed by clinical examination and lumbar magnetic resonance imaging
- Chronic axial low back pain and radicular pain related to lumbar disc herniation
- Low back and/or radicular pain lasting longer than 3 months
- Resting low back and/or radicular pain intensity of ≥5 on a 0-10 visual analog scale
You likely can't join if
- Pregnancy or suspected pregnancy
- Presence of a cardiac pacemaker
- History of epilepsy
- Active or previous malignancy
- History of spinal surgery
- Uncontrolled systemic or psychiatric disease
See the full eligibility criteria
- Age between 18 and 65 years
- Diagnosis of lumbar disc herniation confirmed by clinical examination and lumbar magnetic resonance imaging
- Chronic axial low back pain and radicular pain related to lumbar disc herniation
- Low back and/or radicular pain lasting longer than 3 months
- Resting low back and/or radicular pain intensity of ≥5 on a 0-10 visual analog scale
- Willingness to participate in the study and provide written informed consent
- Pregnancy or suspected pregnancy
- Presence of a cardiac pacemaker
- History of epilepsy
- Active or previous malignancy
- History of spinal surgery
- Uncontrolled systemic or psychiatric disease
- Cauda equina syndrome or progressive neurological deficit
- Peripheral neuropathy, including diabetic or alcohol-related neuropathy
- Neurodegenerative disease
- Acute trauma
- Active systemic infection
- Local infection or skin disease at the injection site or treatment area
- Body mass index greater than 40 kg/m²
- Bleeding disorder that contraindicates treatment
- Spinal stenosis, spondylolysis, or spondylolisthesis
- Neurogenic bladder or bowel syndrome
- Rheumatologic disease
- Arterial vascular disease or vascular claudication
- Receipt of other physical therapy modalities within the last 3 months
- Receipt of spinal injection therapy within the last 3 months
- History of allergy to injection agents
The study team makes the final eligibility decision.
Where it's taking place
- Ankara, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 3 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ankara, Turkey (Türkiye). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.